PolyPid reports positive phase 3 surgical infection drug trial

Dikla Czaczkes Akselbrad  credit: Yossi Lazarov
Dikla Czaczkes Akselbrad credit: Yossi Lazarov

The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery.

Israeli late-stage biopharmaceutical company PolyPid (Nasdaq: PYPD) has reported positive Phase III trial results on its treatment for surgical infections. In 2022, PolyPid's previous trial of the drug failed, which saw its share price fall 77% in one day and continue falling since. Yesterday the share price rose 2.75%, giving a market cap of $34.24 million.

The difference between the trials

The company's product is a delayed-release antibiotic administered in the area where the patient has undergone surgery. PolyPid CEO Dikla Czaczkes Akselbrad explains the difference between the two trials. "The previous trial was conducted during the Covid period, and then there was greater care in protecting against infections, so it was more difficult to prove a difference between our product and the control group. In addition, we saw in the previous trial that while the difference between the control group and the trial was not significant - in one of the subgroups, the one treated after open abdominal surgeries with large incisions, the difference was significant. In agreement with the FDA, we decided to conduct a trial this time that would focus on the group with the large incisions."

The trial was conducted on about 800 subjects, among other things to strengthen its statistical power (the larger the trial, the more likely it is that real differences will also be found to be statistically significant).

Indeed, the trial found that the product clearly met its primary endpoint (a composite measure of infections, mortality, and the need for reoperation) as well as several secondary endpoints. The reduction in the risk of infection after surgery was 58% - a difference that is both clinically and commercially significant, says Czaczkes-Axselbrad. "The product is now ready for approval and is of interest to potential partners," she adds.

The company estimates that it will be possible to submit the product for FDA approval in early 2026. If there are no surprises, and the product receives approval based on this trial, it will probably be possible to market it next year.

Three target groups

Postoperative infections are a common complication, with rates ranging from about 2% in simple surgeries to tens of percent in complex surgeries. Infection can cause severe pain, surgical failure, disability, and even death.

According to PolyPid COO Ori Warshavsky, "Doctors have become accustomed to a certain level of infections, and they see this risk as a necessary price of every surgery. It has been decades since a new technology that truly makes a difference has entered this field - until our product arrived."

PolyPid is currently seeking a partner company to market the product, one that has experience in marketing to surgeons in hospitals in the US. According to Warshavsky, "The product will be marketed to three target groups: surgeons themselves, who are also measured by infection prevention, and if an infection occurs during a surgery they perform, they are summoned to the manager's office; a second group is the infectious disease physicians in hospitals, whose mission is to control infections with minimal use of new antibiotics - that's why our product is so interesting to them, because it doesn't use a new antibiotic but a delayed-release version of a known antibiotic that has no restrictions on its use; and a third group - hospital administrators, who know that they pay for every patient who is readmitted to hospital due to an infection. The cost of an infection is estimated at an additional $20,000, which is paid by the hospital."

For the European market, the company has already signed a marketing agreement with Advanz Pharma. The agreement was signed before the results of the failed trial were published in 2022. According to Czaczkes-Axselbrad, this agreement is continuing as usual, and the trial is also relevant to the product's registration in Europe.

"Investors believed in us"

How did you manage to survive after the failure of the previous trial? Many companies in this situation that are traded on the stock exchange never manage to raise the capital necessary to complete another significant experiment.

Czaczkes-Axselbrad: "Those who continued to believe in us and in the importance of bringing such a product to market were Morris Kahn and his fund, Aurum Ventures. They started investing in us when the company was still private, and supported the IPO. After the trial was unsuccessful, many of the investors who had supported us until then exited the stock or did not continue to invest. It was indeed a difficult time in the market, and fortunately we had investors who believed in us."

PolyPid was founded by Dr. Noam Emanuel and Amir Weisberg at the Xenia Ventures incubator. The company has raised about $240 million to date, in four separate funding rounds, including about $50 million since the results of the last trial were published.

Published by Globes, Israel business news - en.globes.co.il - on June 10, 2025.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2025.

Dikla Czaczkes Akselbrad  credit: Yossi Lazarov
Dikla Czaczkes Akselbrad credit: Yossi Lazarov
Residential towers under construction in Kikar Hamedina, Tel Aviv  credit: Noy Maya Construction costs in Tel Aviv double those in periphery

The Real Estate Appraisers Association has launched a mechanism for estimating construction costs by region and building type.

Tesla V4 Supercharger  credit: PR Ultra-rapid EV chargers on their way to Israel

The new generation of charging stations can fully charge a vehicle battery in five minutes.

Cannabis inhaler co Syqe Medical lays off 50

The company says it is making structural adjustments, mainly in the development department.

Minister of Finance Bezalel Smotrich credit: Noam Moskovitz Knesset Spokesperson Defense Ministry to receive extra NIS 42b

The Ministry of Finance and Ministry of Defense have reached agreement on providing budget supplements for 2025-2026, sources have informed "Globes."

Oren Shoval and Daniel Ramot Photo: PR Via Transportation files confidentially for Wall Street IPO

The Israeli transport solutions company has given no details of the size of the offering, but last time it raised money was at a company valuation of $3.5 billion.

Delek Israel gas station credit: Sivan Faraj Delek Properties completes IPO at reduced valuation

The company raised NIS 173 million from institutional investors at a valuation of NIS 660 million.

BlueWhale unmanned submarine credit: IAI Germany in advanced talks to buy Israeli unmanned sub - report

Germany and Israel are in advanced talks for the sale of Israel Aerospace Industries (IAI) BlueWhale unmanned submarine, "Defense Network" website reports.

Arrow system credit: Ministry of Defense Spokesperson Defense Ministry chief pushing for Israel Aerospace TASE IPO

Since becoming Ministry of Defense director general, Amir Baram has been promoting plans to sell 30% of IAI at a company valuation of NIS 60-80 billion.

Ashtron chairman Rami Nussbaum and CEO Gil Giron credit: Israel Hadari Ashtrom to build power station near Beit Shemesh

Ashtrom, together with Mega Or and Har Tuv will plan and build the Shimshon power plant at an investment of $1 billion.

Enlight's Re'im project in Gaza border area  credit: Belectric Israel C'ttee nixes solar fields in Gaza border settlements

The Committee for the Preservation of Agricultural Land and Open Spaces will sanction only dual-use, agri-voltaic installations in the "granary of Israel."

Israir aircraft credit: Israir Israir awarded US license for Tel Aviv - New York flights

The Israeli airline plans to operate Airbus A330 aircraft on the route on a "dry" lease, with the company's own flight and maintenance crews.

Exodigo management Photo: Exodigo Israeli underground mapping co Exodigo raises $96m

The company has developed underground scanning systems for construction and infrastructure companies, based on technology developed by officers from IDF intelligence units.

Eilat Port in better days credit: Shlomi Yosef Debt ridden Eilat Port to close Sunday

The Eilat Municipality has seized the bank accounts of the Red Sea port due to tax debts of over NIS 600,000.

Air Canada plane at Ben Gurion Airport  credit: Eyal Izhar Air Canada postpones renewal of Israel flights

The airline cited continued geopolitical uncertainty in the region.

Home rental  credit: Eyal Izhar Rents drive inflation, putting interest rate cut in doubt

The housing item accounted for more than a third of the rise in the CPI in June, and is expected to continue to surge.

Pelephone CEO Ilan Sigal credit: Rami Zarnager Pelephone offers NIS 2b for Hot Mobile

Bezeq mobile telephony unit Pelephone has submitted the offer to Patrick Drahi's Altice International, which owns Hot.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018